Circulating Tumor DNA in High Risk Localized Prostate Cancer

NCT07222436 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2025-10-29

No results posted yet for this study

Summary

This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.

Conditions

Sponsors & Collaborators

  • The Beckwith Institute

    collaborator OTHER
  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Leonard J Appleman, MD, PhD · UPMC Hillman Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-23
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07222436 on ClinicalTrials.gov